Navigation Links
Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University
Date:2/24/2011

NEW HAVEN, Conn., Feb. 24, 2011 /PRNewswire/ -- Mira Dx announced today that it has licensed technology from Yale University based on the acceptance of a pivotal breast cancer study in the January issue of the journal Cell Cycle. While numerous BRCA1 coding sequence mutations are associated with breast cancer risk, such mutations in BRCA1 account for less than 5% of breast cancer risk. The research identified microRNA disrupting variants in and around BRCA1 that are polymorphic in breast cancer populations. One key variant (rs8176318) shows significant cancer association for predicting the risk of developing triple negative breast cancer, especially for African American women.

It is estimated that last year in the US more than 207,090 women were diagnosed with breast cancer, and that 39,840 women died from the disease, according to the National Cancer Institute website. Triple negative breast cancer accounts for 15-20% of all breast cancers, and is the most deadly form of this disease.

"There is a real need for tools that can help women who have a family history of breast cancer to better understand their risk," said Martin Van Verhoef, President & CEO of Mira Dx. "We are pleased to continue our advancements in the field of miRNAs in cancer risk and plan to make this information available to women in 2011 in the form of a new triple negative breast cancer risk test." Verhoef continued, "We hope that cancer risk markers such as this marker will provide valuable information for the tens of thousands of women and families each year who are and may be affected by triple negative breast cancer."

Mira Dx was formed in February 2008 by researchers at Yale University to discover gene-based laboratory tests conducted on newly discovered genetic regulators called microRNAs (miRNAs). Mira Dx is applying miRNA discoveries to develop molecular diagnostics, which will provide individualized information on the likelihood of disease occurrence and response to certain types of therapy.

Mira Dx operates a CLIA lab out of New Haven, CT and currently runs a test to identify women at risk of epithelial ovarian cancer, PreOvar. Information on PreOvar and Mira Dx is available from the company's website, www.MiraDx.com.

About Mira DxMira Dx is a genomics company founded on research discovered at Yale University that is dedicated to the development and commercialization of novel microRNA-based tests for risk assessment and companion diagnostics. Our goal is to provide information that can help clinicians better understand cancer to better serve their patients, allowing earlier diagnosis, better management and ultimately higher cure rates.  For more information, please visit www.MiraDx.com.For more information, contact:Stephen Miller, Mira Dxsmiller@miradx.com, 203-789-9000 x206
'/>"/>

SOURCE Mira Dx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
3. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
4. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
5. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
6. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
9. PSKW & Associates LLC Acquires Triax Media, Licenses Triax to Subsidiary, Centricity Group
10. TenX Biopharma Licenses Zanolimumab From Genmab
11. Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Stem cells are primitive cells found in all multi-cellular ... to differentiate into mature cell types Stem cells are ... embryonic stem cells were derived from embryos in 1981, ... culturing of embryonic stem cells from non-human primates occurred ... As a result of these discoveries, stem cells can ...
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
(Date:2/11/2016)...   Health 2.0 , the premiere showcase and ... today " 10 Year Global Retrospective ", a platform ... past ten years.   --> ... has served as the preeminent thought-leader in the health ... technologies, companies, innovators, and patient-activists through an array of ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett is ... these scholarships is to encourage applicants to pursue a degree in their field of ... parishes. , “We have available jobs in St. Landry and Evangeline Parishes that ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... cycle of pharmaceutical products, garnering increased attention from all stakeholders in the development ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... announced that nominations have closed for the ISE Southeast Awards 2016. Finalists and ... announced at the ISE® Southeast Executive Forum and Awards Gala on March 15, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher ... Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare ... System. This will be the first Fisher House in Nevada, and will provide ...
(Date:2/12/2016)... ... February 12, 2016 , ... Erlanger Agency has announced a new partnership in ... latest campaign focuses on the fight against breast cancer, fundraising for a local woman ... here . , Carmen is a loving single mother of two boys who also ...
Breaking Medicine News(10 mins):